marijuana stocks news

Cannabis Sativa, Inc. (CBDS)

Income Statement Get Income Statement for:
View: Annual Data | Quarterly Data All numbers in thousands
Period Ending Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014
Total Revenue 1   4   1   0  
Cost of Revenue 1 0 0 1
Gross Profit (0) 4   1   (1)
Operating Expenses
Research Development 4
Selling General and Administrative 1,780 987 171 100
Non Recurring 13,070
Others
Total Operating Expenses
Operating Income or Loss (1,780) (14,057) (170) (101)
Income from Continuing Operations
Total Other Income/Expenses Net 90 (40)
Earnings Before Interest And Taxes (1,780) (13,968) (210) (101)
Interest Expense 8 8 6 4
Income Before Tax (1,788) (13,975) (216) (104)
Income Tax Expense
Minority Interest
Net Income From Continuing Ops (1,788) (13,975) (216) (104)
Non-recurring Events
Discontinued Operations
Extraordinary Items
Effect Of Accounting Changes
Other Items
Net Income (1,788) (13,975) (216) (104)
Preferred Stock And Other Adjustments
Net Income Applicable To Common Shares (1,788) (13,975) (216) (104)

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

4Front Ventures Corp. (FFNTF) to Report Third Quarter 2022 Financial Results on November 14, 2022

4Front Ventures to Report Third Quarter 2022 Financial Results on November 14,…

$PZOO Wholly Owned Subsidiary, Harris Lee, LLC. Signs Definitive Agreement

Pazoo Wholly Owned Subsidiary, Harris Lee, LLC. Signs Definitive Agreement to be…

HEXO Corp. (HEXO) Files Circular for Special Meeting of Shareholders

HEXO Corp. Files Circular for Special Meeting of Shareholders to Approve Arrangement…

Tetra Bio-Pharma (TBPMF) Discusses FDA Orphan Drug Designation for Its Ophthalmic Program and Cannabinoid-Based Topical Cream

Tetra Bio-Pharma Discusses FDA Orphan Drug Designation for Its Ophthalmic Program and…